Also Known As: Acetyl Octapeptide-3, Acetyl Glutamyl Heptapeptide-3
SNAP-8 (INCI name: Acetyl Octapeptide-3 / Acetyl Glutamyl Heptapeptide-3) is a synthetic N-acetylated, C-terminally amidated octapeptide marketed as an extended derivative of argireline (Acetyl Hexapeptide-3). It is a cosmetic active ingredient and not a pharmaceutical product. The mechanistic hypothesis is that the peptide mimics the SNAP-25 component of the SNARE complex (the vesicular fusion machinery for neuronal acetylcholine release) and thereby competitively dampens muscle contraction in facial mimic muscles. The clinical evidence base is largely manufacturer-driven cosmetic studies; independent peer-reviewed data specific to SNAP-8 is thin, with most cited studies referring to argireline. Limited human data. Research use only.
Studies (mostly on argireline) report that these peptides mimic the SNARE-complex protein SNAP-25 and thereby competitively inhibit vesicular acetylcholine exocytosis at the neuromuscular junction — a "topical botox mimetic" model. Observed in research settings.
Important scoping: direct in-vivo validation of this mechanism through percutaneous penetration and SNAP-25 engagement in human facial muscle is NOT robustly established. Intact-peptide skin penetration is generally limited, which makes cosmetic-peptide claims controversial in dermatology.
The published evidence base is predominantly manufacturer-driven and focused on the parent peptide argireline. SNAP-8-specific peer-reviewed data are thin.
Studies report reduction of visible wrinkles with topical 10 % argireline vs placebo in Chinese subjects (Wang 2013). SNAP-8-specific independent RCTs are thin.
— Wang et al. 2013, Am J Clin Dermatol 14(2):147-153 (PMID 23417317; refers to argireline, NOT SNAP-8)
Observed in research settings
Limited human data. In cosmetic use (topical, low concentrations) SNAP-8 is described as well tolerated. Systemic pharmacovigilance data do not exist.
Wang Y, Wang M, Xiao S, Pan P, Li P, Huo J The anti-wrinkle efficacy of argireline, a synthetic hexapeptide, in Chinese subjects: a randomized, placebo-controlled study American Journal of Clinical Dermatology 2013;14(2):147-153. 2013 .
Blanes-Mira C, Clemente J, Jodas G, Gil A, Fernández-Ballester G, Ponsati B, Gutierrez L, Pérez-Payá E, Ferrer-Montiel A A synthetic hexapeptide (Argireline) with antiwrinkle activity International Journal of Cosmetic Science 2002;24(5):303-310. 2002 .
Lupo MP, Cole AL Cosmeceutical peptides Dermatologic Therapy 2007;20(5):343-349. 2007 .
Endogenous Cu(II)-binding tripeptide (cosmetic ingredient / skin-regeneration research)
Endogenous tripeptide glycyl-L-histidyl-L-lysine (GHK) that avidly chelates Cu(II); INCI-listed cosmetic ingredient "Copper Tripeptide-1", not an FDA-approved drug. Studied for skin remodeling, wound healing, and gene-expression modulation; for research use only.
View DetailsSynthetic Cyclic Heptapeptide (Melanocortin Receptor Class — non-selective MC1R/MC3R/MC4R/MC5R agonist; investigational research compound, not approved)
Synthetic cyclic heptapeptide α-MSH(4–10) analogue (Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH₂); a non-selective melanocortin receptor agonist (MC1R / MC3R / MC4R / MC5R). NOT approved by the FDA, EMA, or MHRA for clinical use; the UK MHRA has issued public warnings against the use of unlicensed Melanotan products since 2008. Limited human data — research use only.
View DetailsMelanocortin Receptor Agonist (predominantly MC1R; α-MSH analogue)
Synthetic superpotent linear α-MSH analogue ([Nle⁴, D-Phe⁷]-α-MSH); MC1R agonist that drives cutaneous eumelanogenesis — approved as Scenesse® by the FDA (2019), EMA (2014) and TGA (2020) for photoprotection in erythropoietic protoporphyria.
View Details